

17703

Access DB# _____

SEARCH REQUEST FORM

Scientific and Technical Information Center

OCT 10 2002

(5110)



Requester's Full Name: Jeffrey E. Russell Examiner #: 62785 Date: 10-10-2002Art Unit: 1654 Phone Number 30 8-3975 Serial Number: 08/236402
Mail Box and Bldg/Room Location: _____ Results Format Preferred (circle): PAPER DISK E-MAIL
CMI-9801 CMI-9807**If more than one search is submitted, please prioritize searches in order of need.**

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Technetium-99m Labeled Imaging AgentsInventors (please provide full names): R. Dean, J. Lister-James, W. McBrideEarliest Priority Filing Date: 5-2-1994

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

Please search the following partial structures:



Z is one of the compounds from groups I or II on the attached sheet, bound to the remainder of the ~~partial~~ partial structure by its amino group so that an amide bond is formed.

Y is one of the compounds from groups I or III on the attached sheet, bound to the remainder of the partial structure by its carboxyl group so that an amide bond is formed.

I'm interested in U.S. patents regardless of their publication date, or any other journal or patent reference published in 1995 or earlier.

Keywords are conjugat?, Tc, technetium, radiolabel? Thank you.

STAFF USE ONLY

Type of Search

Vendors and cost where applicable

Searcher: <u>J. Lister-James</u>	NA Sequence (#):	STN
Searcher Phone #: <u>308-4499</u>	AA Sequence (#):	Dialog
Searcher Location: _____	Structure (#):	Questel/Orbit
Date Searcher Picked Up: _____	Bibliographic	Dr. Link
Date Completed: <u>10/11/02</u>	Litigation	Lexis/Nexis
Searcher Prep & Review Time: _____	Fulltext	Sequence Systems
Clerical Prep Time: _____	Patent Family	WWW/Internet
Online Time: _____	Other	Other (specify) _____

=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 15:14:10 ON 11 OCT 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 11 Oct 2002 VOL 137 ISS 16
FILE LAST UPDATED: 10 Oct 2002 (20021010/ED)


This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=>

=>



=> d stat que
L6 STR



REP G3=(0-2) C
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 15

STEREO ATTRIBUTES: NONE
L10 STR



VAR G1=16/25

REP G4=(2-3) C

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED


GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 21

STEREO ATTRIBUTES: NONE

L17 STR



REP G3=(0-2) C

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED


GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 14

STEREO ATTRIBUTES: NONE

L21 STR




NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 16


STEREO ATTRIBUTES: NONE
 L23 STR



REP G5=(1-2) C
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 12


STEREO ATTRIBUTES: NONE
 L26 56976 SEA FILE=REGISTRY SSS FUL L6 OR L10 OR L17 OR L21 OR L23
 L27 STR



REP G3=(0-2) CH2
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 15

STEREO ATTRIBUTES: NONE
 L28 STR



VAR G1=16/25

REP G4=(2-3) CH2

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED


GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 21

STEREO ATTRIBUTES: NONE

L29 STR



REP G3=(0-2) CH2

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED


GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 14

STEREO ATTRIBUTES: NONE

L30 STR




NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 16

STEREO ATTRIBUTES: NONE
 L31 STR



REP G5=(1-2) CH2

NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE
 L32 600 SEA FILE=REGISTRY SUB=L26 SSS FUL L27 OR L28 OR L29 OR L30 OR
 L31
 L33 5415 SEA FILE=REGISTRY ABB=ON PLU=ON TECHNETI?
 L34 461 SEA FILE=HCAPLUS ABB=ON PLU=ON L32
 L35 95711 SEA FILE=HCAPLUS ABB=ON PLU=ON L33 OR TC OR TECHNETI?
 L36 125 SEA FILE=HCAPLUS ABB=ON PLU=ON L34(L) (L35 OR CONJUGAT? OR
 RADIOLABE?)
 L37 42 SEA FILE=HCAPLUS ABB=ON PLU=ON L36 NOT (2002 OR 2001 OR 2000
 OR 1999 OR 1998 OR 1997 OR 1996)/PY

=>
 =>

=> d ibib abs hitrn l37 1-42

L37 ANSWER 1 OF 42 HCAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1996:611268 HCAPLUS
 DOCUMENT NUMBER: 125:298945
 TITLE: Development of a hormone neutralizing vaccine, using
 GnRH-glycys-PPD, for use in the treatment of
 estrogen-dependent disorders
 AUTHOR(S): Ferro, V. A.; O'Grady, J. E.; Notman, J.; Stimson, W.
 H.
 CORPORATE SOURCE: Department Immunology, University Strathclyde,
 Glasgow, UK
 SOURCE: Therapeutic Immunology (1995), 2(3), 147-157
 CODEN: THIMEY; ISSN: 0967-0149
 PUBLISHER: Blackwell
 DOCUMENT TYPE: Journal

LANGUAGE: English

AB The aim of this study was to develop an effective and nontoxic vaccine, suitable for use in humans, which was capable of effectively controlling estrogen levels. Female Sprague-Dawley rats were immunized with a conjugated analog of gonadotropin releasing hormone, GnRH-glycys-PPD. This resulted in high levels of neutralizing antibody which disrupted GnRH function and consequently caused a redn. in serum estrogen. The effect of estrogen deprivation correlated well with ovarian failure and gonadal atrophy. An examn. was made of various adjuvants in conjunction with the analog to det. the suitability of the combinations in the formulation of an effective human vaccine. This investigation included a novel adjuvant, non-ionic surfactant vesicles (NISV); the results showed that NISV are completely nontoxic and in terms of potentiating and sustaining an immune response, compare favorably with Freund's adjuvant and alum. In addn. the long term effects of immunization were investigated and the data showed that immunoneutralization of GnRH effectively suppresses fertility on a long-term basis.

IT 108635-48-9D, LH-RH glycys, **conjugates** with PPD

RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(hormone-neutralizing vaccine GnRH-glycys-PPD in treatment of estrogen-dependent disorders)

L37 ANSWER 2 OF 42 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1996:59412 HCAPLUS

DOCUMENT NUMBER: 124:197210

TITLE: Sources of radiochemical impurities in the 99mTc/S-unprotected MAG3 system

AUTHOR(S): Noll, B.; Johannsen, B.; Spies, H.

CORPORATE SOURCE: Forschungszentrum Rossendorf, Institut fur Bioanorganische und Radiopharmazeutische Chemie, Dresden, D-01314, Germany

SOURCE: Nuclear Medicine and Biology (1995), 22(8, New Radio-Tracers and Methods of Quality Assurance for Nuclear Medicine Applications), 1057-62
CODEN: NMBIEO; ISSN: 0883-2897

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Impurities in the 99mTc-S-unprotected MAG3 system are examd.

IT 66516-09-4D, Mercaptoacetyltriglycine, **technetium-99 complexes**RL: ANT (Analyte); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(sources of radiochem. impurities in 99mTc/S-unprotected MAG3 system)

L37 ANSWER 3 OF 42 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1995:910371 HCAPLUS

DOCUMENT NUMBER: 123:306747

TITLE: Immunological castration using a gonadotropin-releasing hormone analog conjugated to PPD

AUTHOR(S): Ferro, V. A.; O'Grady, J. E.; Notman, J.; Stimson, W. H.

CORPORATE SOURCE: Todd Centre, University of Strathclyde, Glasgow, G4 ONR, UK

SOURCE: Food and Agricultural Immunology (1995), 7(3), 259-72
CODEN: FAIMEZ; ISSN: 0954-0105

PUBLISHER: Carfax

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The importance of gonadotropin-releasing hormone/LH-releasing hormone (GnRH/LHRH) to reproductive function is illustrated when animals immunized with GnRH produce a high humoral immune response which can achieve a

humane alternative to surgical castration. In this paper, the male rat was used as a model. Rats were immunized with an analog of GnRH, GnRH-glycys, in both its free form and conjugated to the carrier PPD. Pre-immunization priming with BCG was compared with non-BCG priming. The results showed that BCG priming, in the absence of adjuvant, allowed a sufficient redn. in testosterone levels to occur without severely affecting gonadal changes. Immunization in conjunction with adjuvant resulted in high antibody titers, a decrease in testosterone levels, gonadal atrophy and a redn. in spermatogenesis. Alteration of the dose levels of the analog and the long-term effects of immunization on gonadal function were also investigated.

IT 108635-48-9D, LHRH-glycys, conjugates with PPD
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (for immunol. castration)

L37 ANSWER 4 OF 42 HCPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1995:646401 HCPLUS
 DOCUMENT NUMBER: 123:106694
 TITLE: Clinical evaluation of 99mTc-MAG3 as a radiotracer to assess the function of transplanted kidney. Comparison with 123I-OIH
 AUTHOR(S): Yamamoto, Kazutaka; Takahashi, Norio; Sugimoto, Katsuya; Yoshida, Masanori; Hayashi, Nobushige; Ishii, Yasushi; Nishibuchi, Shigeo; Muranaka, Kouji; Okada, Kenichirou; Miyazaki, Masaomi
 CORPORATE SOURCE: Dep. Radiol., Fukui Med. Sch., Fukui, 910-11, Japan
 SOURCE: Nippon Igaku Hoshasen Gakkai Zasshi (1995), 55(6), 409-13
 CODEN: NHGZAR; ISSN: 0048-0428
 DOCUMENT TYPE: Journal
 LANGUAGE: Japanese
 AB We evaluated the clin. usefulness of 99mTc-MAG3 (mercaptopropyl glycyglycylglycine) in 12 cases (7 men and 5 women, aged from 18-57 yr old) with transplanted kidney, and compared it with 123I-OIH (o-iodohippurate). Immediately after bolus injection of 300 MBq of 99mTc-MAG3, 1st pass images (1 frame/3 s for 1 min) and dynamic renal images (1 frame/60 s for 30 min) were recorded. In 10 of 12 cases, the same examn. was carried out using 37 MBq of 123I-OIH within 2 wk. Because of its larger dose and suitable gamma-ray energy, 99mTc-MAG3 provided much better images than 123I-OIH, particularly among 1st pass images. Effective renal plasma flow (ERPF) calcd. from the clearance of 99mTc-MAG3 was less (about 70%) than that of 123I-OIH, however, a strong correlation ($r = 0.98$, $p < 0.001$) was obsd. between the ERPF values of the 2 radiotracers. No adverse effects were caused by 99mTc-MAG3. Our data suggested that 99mTc-MAG3 was a promising radiopharmaceutical with which to evaluate regional dynamic renal function.

IT 66516-09-4D, technetium-99m complexes
 RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (clin. evaluation of technetium-99m-MAG3 as radiotracer to assess the function of transplanted kidney)

L37 ANSWER 5 OF 42 HCPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1995:595617 HCPLUS
 DOCUMENT NUMBER: 123:186758
 TITLE: Investigation of the labeling characteristics of 99mTc-mercaptopropyltriglyceride
 AUTHOR(S): Bormans, G.; Cleynhens, B.; Adriaens, P.; Vanbiljoen, H.; De Roo, M.; Verbruggen, A.
 CORPORATE SOURCE: Faculty of Pharmaceutical Sciences, K. U. Leuven, Louvain, B-3000, Belg.
 SOURCE: Nuclear Medicine and Biology (1995), 22(3), 339-49
 CODEN: NMBIEO; ISSN: 0883-2897

DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB S-Benzyl-, S-benzamidomethyl- and S-benzoylmercaptoacetyltriglycine were synthesized and compared in exchange labeling expts. for the prepn. of ^{99m}Tc -MAG3. The rate of exchange from ^{99m}Tc -tartrate to ^{99m}Tc -MAG3 starting from the resp. precursors was detd. in different conditions. Labeling proceeded most rapidly starting from the S-benzoyl protected precursor but efficient labeling was also accomplished using the more stable S-benzamidomethyl- and S-benzylmercaptoacetyltriglycine. ^{99m}Tc -MAG3 was also prep'd. by direct labeling of unprotected mercaptoacetyltriglycine at alk. pH. Radiochem. purity in these conditions is mainly dependent on the pH during labeling.

IT 66516-09-4DP, Mercaptoacetyltriglycine, **technetium-99**
 complexes
 RL: BUU (Biological use, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. and biodistribution of metastable)

L37 ANSWER 6 OF 42 HCPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1995:528919 HCPLUS
 DOCUMENT NUMBER: 122:299087
 TITLE: Compositions containing benzoylmercaptoacetylglycylglycine and pertechnetate salt-reducing agents for labeled technetium preparations
 INVENTOR(S): Taguchi, Kazumi; Sugino, Osamu
 PATENT ASSIGNEE(S): Daiichi Radioisotope Lab, Japan
 SOURCE: Jpn. Kokai Tokyo Koho, 5 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07041433	A2	19950210	JP 1993-204502	19930728

AB Compns., for labeled Tc preps., comprise benzoylmercaptoacetylglycylglycine (I), which contains enough amt. of mercaptoacetylglycylglycylglycine for chelate formation with Tc, and reducing agents for pertechnetate salts. The labeled Tc preps. are manufd. by dissolving I in solvents, adjusting the pH of the soln. to 6-8, heating the soln. at 55-65.degree., addn. of SnCl₂ to the soln., and adjusting the pH of the soln. to 6-8 again. The labeled Tc preps. are useful for kidney imaging, etc. Na tartrate and I were dissolved in H₂O, from which sol. O had been removed, the soln. was adjusted to pH .apprx.7 with aq. NaOH, stirred at 60.degree. for 25 min, cooled with ice, SnCl₂ was added to the soln., the soln. was adjusted to pH .apprx.7 with aq. NaOH, filled up with H₂O, and freeze-dried to give a compn. The compn. was stirred with ^{99m}Tc -labeled Na pertechnetate injection to give a prepn. contg. ^{99m}Tc -I complex. The prepn. showed radiochem. purity of 93.84%.

IT 66516-09-4, Mercaptoacetylglycylglycylglycine
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (compns. contg. benzoylmercaptoacetylglycylglycylglycine,
 mercaptoacetylglycylglycylglycine, and pertechnetate salt-reducing
 agents for labeled **Tc** preps. for kidney imaging)

L37 ANSWER 7 OF 42 HCPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1995:514103 HCPLUS
 DOCUMENT NUMBER: 123:40909
 TITLE: Effects of generator eluate age on the radiochemical purity of fractionated ^{99}Tcm -MAG3
 AUTHOR(S): Hung, J.C.; Thorson, L.M.
 CORPORATE SOURCE: Department of Diagnostic Radiology, Mayo Clinic,

Rochester, MN, 55905, USA

SOURCE: Nuclear Medicine Communications (1995), 16(3), 157-60
CODEN: NMCODC; ISSN: 0143-3636DOCUMENT TYPE: Journal
LANGUAGE: English

AB The fractionation of US mercaptoacetyltriglycine (MAG3) cold kits provides an economical way of prep. ^{99m}Tc -MAG3. However, our nuclear pharmacy noted that fractionated ^{99m}Tc -MAG3 kits sometimes failed radiochem. purity (RCP) testing (i.e., RCP <90%) when a ^{99m}Tc eluate of older age was used. The purpose of this study was to evaluate the effects of eluate age on the radiochem. purity of fractionated ^{99m}Tc -MAG3 kits. Each of four US MAG3 cold kits was initially dild. with 10 mL N2-purged 0.9% NaCl soln. and subdivided into 10 aliquots of 1 mL MAG3 soln. and overlaid with N2. The 40 fractionated MAG3 vials were immediately frozen at -20.degree.C for storage. Fractionated MAG3 kits were reconstituted with 1 mL of .apprx.111 GBq ^{99m}Tc eluate from a long-ingrowth generator (i.e., .gtoreq.72 h) every hour during the 6 h postelution period.

IT 66516-09-4D, Mercaptoacetyltriglycine, technetium-99 complexes

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(generator eluate age effect on radiochem. purity of fractionated ^{99m}Tc -MAG3)

L37 ANSWER 8 OF 42 HCPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1994:552251 HCPLUS

DOCUMENT NUMBER: 121:152251

TITLE: Measurement of the extravascular concentration of renal agents following intravenous bolus injection

AUTHOR(S): Peters, A.M.; Brown, H.; Cosgriff, P.

CORPORATE SOURCE: Dep. Diagn. Radiol., Hammersmith Hosp., London, UK

SOURCE: Nuclear Medicine Communications (1994), 15(2), 46-72
CODEN: NMCODC; ISSN: 0143-3636DOCUMENT TYPE: Journal
LANGUAGE: English

AB The extravascular concn. (C_e) of some renal agents, in relation to the simultaneous plasma concn. (C_i), was calcd. as a function of time after i.v. injection. Four agents were studied: ^{51}Cr -EDTA ($n = 11$), ^{125}I -hippuran ($n = 11$), ^{99m}Tc -dimercaptosuccinic acid (DMSA) ($n = 11$) and ^{99m}Tc -mercaptoacetyltriglycine MAG3 ($n = 20$). Plasma clearance curves were constructed from data acquired from multiple blood sampling and fitted with two exponentials. The extravascular content of tracer at any time is equal to the injected dose remaining after subtraction of the intravascular tracer content and the total amt. of tracer cleared from plasma. Mean C_e/C_i at equil. (defined as the time, >120 min, when C_e/C_i reaches its max. value) was 1.087 (S.D. 0.019) for EDTA, 1.73 (0.48) for hippuran, 0.37 (0.2) for DMSA and 0.64 (0.3) for MAG3. Corresponding clearance (F) values were 68 (13), 415 (149), 15.6 (9.5) and 214 (52) mL min $^{-1}$ 1.73 m^{-2} . C_e/C_i correlated with F and was also related to protein binding in plasma. Extrapolation of the regressions of C_e/C_i on F to $F = 0$ at several time points after injection gives a curve of C_e/C_i (at $F = 0$) against time which represents the rate of equilibration of the tracer throughout its distribution vol. that would be seen with zero clearance, and therefore allows measurement of the in vivo protein binding of the tracer in plasma. Protein binding was zero for EDTA, 30% for hippuran, 86% for DMSA and 88% for MAG3. C_e/C_i may be higher than expected from protein binding if the plasma clearance of the tracer is rapid, as for hippuran and MAG3, and may introduce error into plasma clearance curves based on gamma camera blood pool regions of interest.

IT 66516-09-4D, Mercaptoacetyltriglycine, technetium-99 complexes

RL: BIOL (Biological study)
(kidney scintigraphy agent, extravascular concn. detn. of)

L37 ANSWER 9 OF 42 HCPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1994:453220 HCPLUS
 DOCUMENT NUMBER: 121:53220
 TITLE: Labeling of sulfur-containing glycine derivatives with Tc-99m radionuclide
 AUTHOR(S): Kornyei, Jozsef; Torko, Janos; Volford, Janos;
 Sztaricskai, Ferenc
 CORPORATE SOURCE: Izotop Intez. Kft, Budapest, H-1525, Hung.
 SOURCE: Magyar Kemial Folyoirat (1994), 100(4), 189-92
 CODEN: MGKFA3; ISSN: 0025-0155
 DOCUMENT TYPE: Journal
 LANGUAGE: Hungarian

AB Mercaptoacetyltriglycine and its related compds. were synthesized and labeled with Tc-99m-radionuclide to study the effect of some substituents and labeling conditions upon the formation of radioactive byproducts. Direct labeling and ligand exchange reactions were carried out followed by the radio-TLC sepn. The direct labeling in alk. media at elevated temp. provides high radiochem. yields and offers opportunity for a new kit formulation because the neutralization to the physiol. pH does not cause any change in the chem. identity of the complexes. Compds. with strongly polar sulfonyl group show significantly lower protein binding compared with mercaptoacetyltriglycine and may be considered as potential renal agents.

IT 66516-08-3, Mercaptoacetyltriglycine 66516-09-4,
 Mercaptoacetyltriglycine
 RL: BIOL (Biological study)
 (**technetium**-99m labeling of, for kidney imaging)

L37 ANSWER 10 OF 42 HCPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1994:259847 HCPLUS
 DOCUMENT NUMBER: 120:259847
 TITLE: Occurrence and nature of different Tc(V) and Re(V) complexes with mercapto/amide ligands
 AUTHOR(S): Johannsen, B.; Noll, B.; Leibnitz, G.; Reck, G.; Noll, St.; Spies, H.
 CORPORATE SOURCE: Inst. Bioanorg. Radiopharm. Chem., Forschungszent., Dresden, D-01314, Germany
 SOURCE: Radiochimica Acta (1993), 63, 133-7
 CODEN: RAACAP; ISSN: 0033-8230
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB The ligand exchange reaction of Tc(V) gluconate and Re(V) gluconate was carried out with mercaptoacetyl triglycine (MAG3), mercaptoacetyl diglycine (MAG2) and mercaptoacetyl glycine (MAG1) as well as their Me esters. In dependence on the ligand/metal molar ratio up to 3 complexes are obtained. A single x-ray structure detn. was carried out for the Ph₄As⁺ salt of [TcO(MAG2)]⁻. MAG2 Me ester and MAG1 form 2:1 complexes as the main products.

IT 66516-08-3DP, **technetium** complexes 66516-09-4DP
 , **technetium** complexes 154150-08-0DP, rhenium and
technetium complexes 154150-09-1DP, **technetium**
 complexes
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prep. of)

L37 ANSWER 11 OF 42 HCPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1994:186299 HCPLUS
 DOCUMENT NUMBER: 120:186299
 TITLE: 99mTc-labeling of mercaptoacetyltriglycine and its related compounds
 AUTHOR(S): Kornyei, J.; Torko, J.; Volford, J.
 CORPORATE SOURCE: Inst. Isot. Co. Ltd., Budapest, H-1121, Hung.

SOURCE: Journal of Radioanalytical and Nuclear Chemistry
 (1994), 186(2), 189-97
 CODEN: JRNCM; ISSN: 0236-5731

DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Mercaptoacetyltriglycine and its related compds. were synthesized and labeled with ^{99m}Tc to study the effect of substituents and labeling conditions upon the formation of radioactive byproducts. Direct labeling and ligand exchange reactions were followed by radio-TLC sepn. The direct labeling in alk. media at elevated temp. provides high radiochem. yields and gives an opportunity for a new kit formulation because the neutralization to physiol. pH does not cause any change in the chem. identity of the complexes. Compds. with the strongly polar sulfonyl groups show significantly lower protein binding compared with mercaptoacetyltriglycine and may be considered as potential renal agents.

IT 66516-08-3, Mercaptoacetyltriglycine 66516-09-4,

Mercaptoacetyltriglycine

RL: BIOL (Biological study)

(technetium-99m labeling of kidney scintigraphy in relation to)

L37 ANSWER 12 OF 42 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1994:93865 HCAPLUS

DOCUMENT NUMBER: 120:93865

TITLE: Technetium and rhenium complexes of mercapto-containing peptides. 1. Tc(V) and Re(V) complexes with mercaptoacetyl diglycine (MAG2) and X-ray structure of AsPh₄[TcO(MAG2)].cntdot.C₂H₅OH

AUTHOR(S): Johannsen, Bernd; Noll, Bernhard; Leibnitz, Peter; Reck, Guenter; Noll, Steffi; Spies, Hartmut

CORPORATE SOURCE: Forschungszentrum Rossendorf e.V., Institut fuer Bioanorganische und Radiopharmazeutische Chemie, POB 19, Dresden, D-8051, Germany

SOURCE: Inorganica Chimica Acta (1993), 210(2), 209-14

CODEN: ICHAA3; ISSN: 0020-1693

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The reaction of mercaptoacetyl diglycine (MAG2) with Tc(V) gluconate in aq. soln. produced [TcO(MAG2)]⁻. A single-crystal x-ray structure detn. was carried out for the AsPh₄⁺ salt. The dark brown crystals are monoclinic, space group P21/n, a 12.478(5), b 14.922(5), c 17.183(9) .ANG., .beta. 103.13(4).degree., Z = 4, R = 0.033. [TcO(MAG2)]⁻ has a square pyramidal geometry with the Tc displaced by 0.756 .ANG. towards the oxo ligand from the plane formed by the equatorial S,N,N,O atoms. AsPh₄[ReO(MAG2)] was prep'd. analogously starting from Re(V) gluconate and characterized.

IT 66516-08-3P, Mercaptoacetyl diglycine

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and reaction of, with rhenium or technetium gluconates)

L37 ANSWER 13 OF 42 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1993:685181 HCAPLUS

DOCUMENT NUMBER: 119:285181

TITLE: Method for preparation of metal complexes of sulfur-containing amino acid derivatives

INVENTOR(S): Biro, Gyula; Imre, Janos; Kern, Jozsef; Kornyei, Jozsef

PATENT ASSIGNEE(S): MTA Izotopkutato Intezet, Hung.

SOURCE: Hung. Teljes, 15 pp.

CODEN: HUXXBU

DOCUMENT TYPE: Patent

LANGUAGE: Hungarian


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
HU 59931	A2	19920728	HU 1990-8351	19901220

OTHER SOURCE(S): MARPAT 119:285181

GI



AB The homonuclear title complexes [I; X = N(CH₂)₁₋₁₂COOR (R = H or C₁₋₃ alkyl); X₁ and X₂ are sep. H atoms or they together represent 1 oxo group; X₃ = H, X₄ = COOR₁ (R₁ = H, Et, or iso-Pr) or X₃ and X₄ together represent 1 oxo group; X₅ = H or COOR₂ (R₂ = H, Et, iso-Pr or (CH₂)₁₋₁₂OH); X₆ and X₇ are sep. H atoms or they together represent 1 oxo group; M = metal] (radioisotope labeled of required) are prep'd. by reacting a soln. of the reagent [II; where X₁, X₂, X₃, X₄, X₅, X₆, and X₇ are the same substituents as above and X = SH or NH(CH₂)₁₋₁₂R] with M₁(HEO₄)₂.(1-8)H₂O (M₁ = Ce, Ti, and Zr; E = As, P, S), removing the solvent, and interacting the product with MA (A = anion). The complexes are well defined. Complexes with high specific radioactivity can be prep'd. simply. Their in vitro and in vivo stability is improved. A no. of additives and complex buffer systems are obviated. The insol. inorg. matrix is removed in a single step by bacterium filtration assuring the sterility and pyrogen-free nature of the resultant metal complex solns. Expensive subsequent purifn. is completely obviated. Thus, mercaptoacetyltriglycine 4 mmol was reacted as 0.05 mL/dm³ aq. soln. soln. with cryst. Zr(HPO₄)₂ hydrate 30.2 mg at lab. temp. for 4 h. The solvent was removed by lyophilization and the ampul was closed. Radioactive labeling was carried out by isotope exchange with carrier-free ¹¹¹In-InCl₃ (.1toreq.185 Mbq/ampul) for 15 min. Sterility was assured by Millipore filtration (0.22 .mu.m). The resultant labeled complex is suitable for kidney studies.

IT 66516-09-4, Mercaptoacetyltriglycine

RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in prepn. of **radiolabeled** metal complexes)

L37 ANSWER 14 OF 42 HCPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1993:512284 HCPLUS

DOCUMENT NUMBER: 119:112284

TITLE: Diagnostic radiopharmaceutical dose estimate to the Australian population

AUTHOR(S): Colmanet, Silvano F.; Samuels, David L.

CORPORATE SOURCE: Aust. Radiat. Lab., Yallambie, 3085, Australia

SOURCE: Health Physics (1993), 64(4), 375-80

CODEN: HLTPAO; ISSN: 0017-9078

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The annual per caput ED and the genetically significant dose to the Australian population, arising from the practice of nuclear medicine, were estd. from the results of a survey of all major hospitals. The survey was

conducted for a 4-wk time period during June-July 1991. Patients were characterized by age and gender. The use of diagnostic radiopharmaceuticals resulted in values of 64 .mu.Sv and 26 .mu.Sv per caput for ED and the genetically significant dose, resp. The ED has shown a marked increase in the last decade. These values may be compared to the estd. 2 mSv from natural background radiation.

IT 66516-09-4D, technetium-99m complexes

RL: PROC (Process)

(dosimetry of, in population in Australia from diagnostic radiol.)

L37 ANSWER 15 OF 42 HCPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1993:164242 HCPLUS

DOCUMENT NUMBER: 118:164242

TITLE: Determination of radiochemical and chemical purity of technetium-99m-mercaptoacetyltriglycine radiopharmaceutical preparation and of the parent compound by RP HPLC method

AUTHOR(S): Lengyel, J.; Angelis, B.

CORPORATE SOURCE: Nucl. Res. Inst., Rez, Czech.

SOURCE: Nucleon (Rez, Czech Republic) (1992), (4), 21-4
CODEN: NLEQEM; ISSN: 1210-2660

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Chem. and radiochem. purities of a raw substance (benzoylmercaptoacetyltriglycine produced at the NRI Rez) and of the chelate of mercaptoacetyltriglycine with 99mTc were detd. by using RP HPLC method. The chem. purity of benzoylmercaptoacetyltriglycine obtained by this method is equal to or higher than 99.70% and the radiochem. purity of 99mTc mercaptoacetyltriglycine is higher than 98%.

IT 66516-09-4D, technetium-99 complexes

RL: PRP (Properties)

(purity of, reversed-phase HPLC for detn. of)

L37 ANSWER 16 OF 42 HCPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1993:141585 HCPLUS

DOCUMENT NUMBER: 118:141585

TITLE: Nuclear translocation of aflatoxin B1-protein complex

AUTHOR(S): Ch'ih, John J.; Ewaskiewicz, Joseph I.; Taggart, Pamela; Devlin, Thomas M.

CORPORATE SOURCE: Sch. Med., Hahnemann Univ., Philadelphia, PA, 19102-1192, USA

SOURCE: Biochemical and Biophysical Research Communications (1993), 190(1), 186-91
CODEN: BBRCA9; ISSN: 0006-291X

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The in vitro binding of [3H]aflatoxin B1 (AFB1) to various proteins was studied by equil. dialysis. At 23.degree., [3H]AFB1 binding activity (mmol/mol) decreased as follows: pyruvate kinase > albumin-nuclear localization sequence (NLS) > albumin-NLS > albumin > carbonic anhydrase > RNase > histones. The nuclear translocation and activation of AFB1 and AFB-protein complexes was investigated using isolated rat liver nuclei in the presence of ATP and a NADPH regenerating system. Proteins contg. NLS such as histones and albumin-NLS facilitated AFB1 translocation into the nucleus where activation and adduct formation took place.

IT 146509-03-7D, conjugates with albumin

RL: BIOL (Biological study)

(binding of, with aflatoxin B1, aflatoxin B1-protein complex liver nuclear translocation in relation to)

L37 ANSWER 17 OF 42 HCPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1993:120055 HCPLUS

DOCUMENT NUMBER: 118:120055

TITLE: Clearance and distribution parameters of ^{99m}Tc -EHIDA, -DTPA and -MAG-3 by dynamic liver/kidney scintigraphy
 AUTHOR(S): Blaha, V.; Cihak, I.; Nicek, F.
 CORPORATE SOURCE: Med. Sch., Charles Univ., Srobarova, 48 100 42, Czech.
 SOURCE: Nuclear Medicine and Biology (1993), 20(1), 89-93
 CODEN: NMBIEO; ISSN: 0883-2897

DOCUMENT TYPE: Journal
 LANGUAGE: English

AB The radiopharmaceuticals (RF) EHIDA, DTPA, and MAG-3 (labeled by ^{99m}Tc), commonly used in dynamic liver/kidney scintigraphy, are distributed in intravascular (i.v.) and extravascular (e.v.) spaces, as they are simultaneously cleared from the blood passing through their target organ (liver/kidney). The drop in concn. of these RF in blood is therefore detd. by distribution as well as by clearance up to the time of equil. From that time, only the rate of decrease of RF in blood expresses the "true" (liver/kidney) clearance and this clearance parameter is a clin. reliable index of the function of the target organ. The method of anal. of the clearance curve obtained from the heart region has been reported; the method is based on a physiol. approach with respect to the distribution processes of the RF in the organism. The results of 218 patients examd. using ^{99m}Tc -EHIDA, 192 using -DTPA, and 65 using -MAG-3 have been statistically processed. The main purpose of the work was to obtain the reliable clearance parameters of the RF with extravascular distribution for routine clin. practice. The 2nd purpose was to contribute to the knowledge regarding the distribution processes of these compds. in their distribution spaces.

IT 66516-09-4D, technetium-99 complexes

RL: BIOL (Biological study)
 (clearance and biodistribution of, kidney and liver scintigraphy in relation to)

L37 ANSWER 18 OF 42 HCPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1992:647830 HCPLUS
 DOCUMENT NUMBER: 117:247830
 TITLE: Studies on new technetium-99m-labeled renal imaging agents. II. Synthesis of technetium-99m-MAG2 and imaging comparison with technetium-99m-MAG3 and technetium-99m-DTPA
 AUTHOR(S): Luo, Shunzhong; Liu, Zhonglin; Zhao, Pengji; Fu, Yibei; Liu, Shijun
 CORPORATE SOURCE: Southwest Inst. Nucl. Phys. Chem., Chengdu, Peop. Rep. China
 SOURCE: Tongweisu (1991), 4(3), 137-42
 CODEN: TONGEM; ISSN: 1000-7512
 DOCUMENT TYPE: Journal
 LANGUAGE: Chinese

AB Changing the length of the peptide chain of MAG3 (mercaptoacetyltriglycine), a new ligand, Bz-MAG2 (benzoylthioacetyl diglycine), was synthesized. The effects of the pH value, reaction temp., and reaction time on the formation of ^{99m}Tc -MAG2 were studied and a prepn. procedure with a complexing yield up to 98% was established. In rabbit kidneys, both the imaging quality and excretion rate of ^{99m}Tc -MAG2 were superior to those of ^{99m}Tc -DPTA but slightly inferior to those of ^{99m}Tc -MAG3.

IT 66516-08-3DP, technetium-99 complexes

RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of and scintigraphy with, of kidney)

L37 ANSWER 19 OF 42 HCPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1992:627232 HCPLUS
 DOCUMENT NUMBER: 117:227232
 TITLE: Gene transfer into hepatocytes using asialoglycoprotein receptor mediated endocytosis of

AUTHOR(S): DNA complexed with an artificial tetra-antennary galactose ligand
 Plank, Christian; Zatloukal, Kurt; Cotten, Matt;
 Mechtler, Karl; Wagner, Ernst

CORPORATE SOURCE: Res. Inst. Mol. Pathol., Vienna, A-1030, Austria

SOURCE: Bioconjugate Chemistry (1992), 3(6), 533-9

DOCUMENT TYPE: CODEN: BCCHE; ISSN: 1043-1802

LANGUAGE: English

AB An artificial ligand for the hepatocyte-specific asialoglycoprotein receptor was developed for the purpose of generating a synthetic delivery system for DNA. This ligand has a tetra-antennary structure, contg. 4 terminal galactose residues on a branched carrier peptide. The carbohydrate residues of this glycopeptide were introduced by reductive coupling of lactose to the .alpha.- and .epsilon.-amino groups of the 2 N-terminal lysines on the carrier peptide. The C-terminus of the peptide, contg. a cysteine sepd. from the branched N-terminus by a 10-amino acid spacer sequence, was used for conjugation to 3-(2-pyridylidithio)propionate-modified polylysine via disulfide bond formation. Complexes contg. plasmid DNA bound to these galactose-polylysine conjugates have been used for asialoglycoprotein receptor-mediated transfer of a luciferase gene into human (HepG2) and murine (BNL CL.2) hepatocyte cell lines. Gene transfer was strongly promoted when amphipathic peptides with pH-controlled membrane-disruption activity, derived from the N-terminal sequence of influenza virus hemagglutinin HA-2, were also present in these DNA complexes. Thus, the small functional domains of two large proteins, asialoglycoprotein and hemagglutinin, were borrowed and were assembled into a supramol. complex to generate an efficient gene-transfer system.

IT **144269-59-0DP, polylysine conjugate**

RL: PREP (Preparation)
 (prepn. and use in asialoglycoprotein receptor-mediated gene transfer of)

L37 ANSWER 20 OF 42 HCAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1992:566771 HCAPLUS
 DOCUMENT NUMBER: 117:166771
 TITLE: Preparation of the renal function and imaging agent technetium-99m-MAG3 starting from S-unprotected mercaptoacetyltriglycine
 AUTHOR(S): Noll, B.; Johannsen, B.; May, K.; Spies, H.
 CORPORATE SOURCE: Cent. Inst. Nucl. Res., Rossendorf, Dresden, 8051, Germany
 SOURCE: Applied Radiation and Isotopes (1992), 43(7), 899-901
 DOCUMENT TYPE: CODEN: ARISEF; ISSN: 0883-2889

LANGUAGE: English

AB A new approach that obviates inconvenient heating of the labeling soln. when prep. the renal function and imaging agent 99mTc-MAG3 is described. The labeling procedure involves redn. of 99mTc-generator eluate with SnCl₂ in alk. soln. in the presence of S-unprotected mercaptoacetyltriglycine (MAG3) and the coligand sodium tartrate, followed by neutralization with a phosphate buffer soln. After optimization of the kit prepn. the radiochem. purity of the radiopharmaceutical amts. to >98%. During the labeling process intermediate Tc-species occur.

IT **66516-09-4P**

RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and complexation of, with **technetium-99m**)

IT **66516-08-3DP, technetium 99 complexes**

66516-09-4DP, technetium 99 complexes

RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of and renal function imaging by)

ACCESSION NUMBER: 1992:518497 HCAPLUS
 DOCUMENT NUMBER: 117:118497
 TITLE: Antibody conjugates for targeted drug delivery
 INVENTOR(S): Morgan, Alton C., Jr.; Srinivasan, Ananthachari; Reno,
 John M.; Fritzberg, Alan R.; Anderson, David C.
 PATENT ASSIGNEE(S): NeoRx Corp., USA
 SOURCE: U.S., 22 pp. Cont.-in-part of U.S. Ser. No. 157,895
 abandoned.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5106951	A	19920421	US 1989-332610	19890331
EP 329184	A2	19890823	EP 1989-102809	19890217
EP 329184	A3	19900523		
R: DE, FR, GB, IT, SE				
PRIORITY APPLN. INFO.:			US 1988-157895	19880219
			EP 1989-102809	19890217

AB Drugs are complexed with complementary structure (csDBM), which bind noncovalently with the drug and covalently to a targeting antibody or carrier. The noncovalent binding does not compromise the potency of the drug. FMN, used as csDBM for doxorubicin, was 1st derivatized with maleimide, then complexed with doxorubicin, followed by conjugation with an antibody.

IT 143090-37-3 143090-38-4 143090-39-5

RL: BIOL (Biological study)
 (doxorubicin binding by, for complexation and conjugation in targeted drug delivery systems)

L37 ANSWER 22 OF 42 HCAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1992:507807 HCAPLUS
 DOCUMENT NUMBER: 117:107807
 TITLE: Use of fibronectin having a variably included Type III repeat sequence as a marker for toxemia in pregnancy and immunoassay
 INVENTOR(S): Peters, John H.; Lockwood, Charles J.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S., 9 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5108898	A	19920428	US 1989-298622	19890118

AB The elevation, in a pregnant woman, of human cellular fibronectin monomers having a variably included Type III repeat, as early as the 1st trimester, has been found to precede the onset of the clin. manifestations of toxemia and correlate with the severity of the disease state. Antibodies to ED1 or ED2 Type III repeat region (sequences presented) are used in immunoassays to det. the amt. of fibronectin having a variably included Type III repeat in a body fluid sample. A 29-amino acid residue peptide having the sequence: TYSSPEDGIHELFPAPDGEEDTAELQGGC (based on ED1) was synthesized, coupled to keyhole limpet hemocyanin, and used to raise antibodies in goats. The antibodies were used in an ELISA of blood plasma samples from pregnant women.

IT 142770-36-3D, hemocyanin conjugates

RL: ANST (Analytical study)
 (for antibodies prodn. for toxemia of pregnancy ELISA)

L37 ANSWER 23 OF 42 HCAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1991:578869 HCAPLUS
 DOCUMENT NUMBER: 115:178869
 TITLE: Two-component kit with nonradioactive precursor for
 the preparation of an enantiomeric form of the liver
 function diagnostic agent, technetium-99m-labeled
 mercaptoacetyltriglycine
 INVENTOR(S): Noll, Bernhard; Johannsen, Bernd; Muenze, Rudolph;
 Spies, Hartmut
 PATENT ASSIGNEE(S): Zentralinstitut fuer Kernforschung Rossendorf, Germany
 SOURCE: Eur. Pat. Appl., 4 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 427360	A2	19910515	EP 1990-250271	19901023
EP 427360	A3	19910605		
EP 427360	B1	19940615		
R: AT, DE, FR, GR, IT, NL				
DD 288751	A5	19910411	DD 1989-334034	19891030
DD 288751	B5	19940721		
DD 288752	A5	19910411	DD 1989-334035	19891030
DD 288752	B5	19940609		
HU 58920	A2	19920330	HU 1990-6944	19901030
HU 206774	B	19921228		
CZ 278025	B6	19930317	CZ 1990-5316	19901030
SK 277878	B6	19950607	SK 1990-5316	19901030
PRIORITY APPLN. INFO.:			DD 1989-334034	19891030
			DD 1989-334035	19891030

AB The 1st kit component comprises a lyophilized mixt. of mercaptoacetyltriglycine (MAG-3), a coligand which stabilizes the oxidn. stage +5 of Tc, a reducing agent, and an alkali metal or alk.-earth metal hydroxide. The coligand is a tartrate or gluconate. The 2nd kit component is a phosphate buffer soln., contg. acid corresponding to a molar ratio of MAG-3/hydroxide. MAG-3 was prep'd. by sapon. of benzoyl-MAG-3 with NaOMe in MeOH. A kit was made, having as a 1st component a mixt. of MAG-3 0.2, di-Na tartrate-2H2O 22, NaOH 1.72 mg, and 60 .mu.g SnCl2.2H2O, and as the 2nd component a mixt. of 0.1M Na2HPO4 1.638, 0.1M NaH2PO4 0.382, and 1N HCl 0.04 mL. Prior to use, the 1st component was labeled with 99mTc reactor eluate and mixed with the 2nd component.

IT 66516-09-4D, technetium-99 complexes

RL: PROC (Process)
 (as kidney function diagnostic agent, kit for prepn. of)

IT 66516-09-4

RL: ANST (Analytical study)
 (kit contg., for prepn. of metastable technetium-99-labeled diagnostic agent for kidney function detn.)

L37 ANSWER 24 OF 42 HCAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1991:499411 HCAPLUS
 DOCUMENT NUMBER: 115:99411
 TITLE: Polyamide conjugates with peptide containing helper T-cell epitope as site-directed immunologic agents
 INVENTOR(S): Arlinghaus, Ralph B.; Sparrow, James T.
 PATENT ASSIGNEE(S): University of Texas System, USA

SOURCE: PCT Int. Appl., 51 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9015627	A1	19901227	WO 1990-US767	19900209
W: AT, AU, BB, BG, BR, CA, CH, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MC, MG, MW, NL, NO, RO, SD, SE, SU				
RW: AT, BE, BF, BJ, CF, CG, CH, CM, DE, DK, ES, FR, GA, GB, IT, LU, ML, MR, NL, SE, SN, TD, TG				
US 5126399	A	19920630	US 1989-368713	19890620
AU 9059581	A1	19910108	AU 1990-59581	19900209
PRIORITY APPLN. INFO.:			US 1989-368713	19890620
			US 1986-858216	19860430
			US 1989-368708	19890619
			WO 1990-US767	19900209

AB Peptidyl-resin conjugates are made of an immunogenic/antigenic peptide conjugated to a polyamide resin, wherein the peptide incorporates a helper T-cell epitope. The inclusion of a T-cell epitope in this peptide sequence provides benefits in the prepn. of site-directed reagents intended as immunogens. A synthetic peptide predicted from Abelson murine leukemia virus abl oncogene (residues 389-403) was synthesized with a T-cell active epitope of 7 amino acids placed at its N-terminus (T-abl-resin). The T-abl-resin construct stimulated the immune response in rabbits, giving significantly higher specific antibody titers than abl-resin controls. The conjugates may be used in immunoassays and manufg. vaccines.

IT 135236-49-6DP, conjugate to polyimide resin

RL: PREP (Preparation)
(prepn. of, as site-directed immunogen)

L37 ANSWER 25 OF 42 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1991:400778 HCAPLUS

DOCUMENT NUMBER: 115:778

TITLE: Covalently-linked complexes and methods for enhanced cytotoxicity and imaging

INVENTOR(S): Anderson, David C.; Morgan, A. Charles; Abrams, Paul G.; Nichols, Everett J.; Fritzberg, Alan R.

PATENT ASSIGNEE(S): NeoRx Corp., USA

SOURCE: Eur. Pat. Appl., 23 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 359347	A2	19900321	EP 1989-250014	19890814
EP 359347	A3	19900418		
EP 359347	B1	19921223		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 5135736	A	19920804	US 1988-232337	19880815
US 5169933	A	19921208	US 1989-390241	19890807
CA 1334513	A1	19950221	CA 1989-608198	19890811
JP 02124833	A2	19900514	JP 1989-209992	19890814
AT 83669	E	19930115	AT 1989-250014	19890814
PRIORITY APPLN. INFO.:			US 1988-232337	19880815
			EP 1989-250014	19890814

- AB Covalently-linked complexes (CLCs) for targeting a defined population of cells comprise a targeting protein (e.g. antibody, hormone, enzyme, etc.), a cytotoxic agent (e.g. radionuclide, toxin, drug, etc.) an enhancing moiety capable of enhancing CLC-target cell interaction (e.g. a translocating/internalizing moiety, an anchoring peptide, membrane-sol. hydrophobic mol., etc.). The CLCs are used to enhance in vivo cytotoxicity and imaging (no data). Translocating peptide, Cys-Gly-Glu-Ala-Ala-Leu-Ala(Glu-Ala-Leu-Ala)4-Glu-Ala-Leu-Glu-Ala-Ala-NH₂, is conjugated via succinimidyl 4 (N-maleimidemethyl)cyclohexane-1-carboxylate (SMCC) to reduced toxin A chain. The conjugate is reacted with iminothiolane to generate further thiol groups which are then bonded to reduced antibody to prep. translocating peptide-ricin A chain-antibody CLC.
- IT 131399-96-7D, **conjugates** with cytotoxic agent and targeting protein 131400-07-2D, **conjugates** with cytotoxic agent and targeting protein 131400-08-3D, **conjugates** with cytotoxic agent and targeting protein
 RL: BIOL (Biological study)
 (cell targeting with, for enhanced cytotoxicity and imaging)

- L37 ANSWER 26 OF 42 HCAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1991:139080 HCAPLUS
 DOCUMENT NUMBER: 114:139080
 TITLE: Rhenium-186 radioimmunotherapy of small cell lung carcinoma xenografts in nude mice
 AUTHOR(S): Beaumier, Paul L.; Venkatesan, Prasanna; Vanderheyden, Jean Luc; Burgua, William D.; Kunz, Lawrence L.; Fritzberg, Alan R.; Abrams, Paul G.; Morgan, Alton C., Jr.
 CORPORATE SOURCE: NeoRx Corp., Seattle, WA, 98119, USA
 SOURCE: Cancer Research (1991), 51(2), 676-81
 CODEN: CNREA8; ISSN: 0008-5472
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB A 186Re-labeled monoclonal antibody (MAb), NR-LU-10, was used for the radioimmunotherapy of a s.c. human small cell lung carcinoma xenograft, SHT-1, in nude mice. Biodistribution with specific and irrelevant labeled MAb demonstrated peak tumor uptake of 8% and 3% of the injected dose/g at 2 days, resp. Dosimetry anal. predicted tumor:whole-body radiation-absorbed dose ratios of 2.43:1 for NR-LU-10 and 0.62:1 for irrelevant MAb. Single-dose toxicity screening estd. a 50% LD within 30 days of 600 .mu.Ci (880 cGy of whole-body radiation). As anticipated, a multiple-dose regimen of 490 .mu.Ci in 4 doses over 10 days (720 cGy of whole-body radiation, 8 of 8 surviving >30 days) was less toxic than a single bolus dose of 430 .mu.Ci (644 cGy of whole-body radiation, 6 of 8 surviving >30 days). A multidose radioimmunotherapy regimen was initiated in nude mice bearing 66-mm³ tumors (total dose, 500-600 .mu.Ci). Complete remissions (>140 days) were achieved in 3 of 16 mice, and the remainder showed a mean tumor growth delay of 53 days. Matched doses with irrelevant MAb produced 1 remission, 1 treatment-related death, and a mean growth delay of only 20 days in 6 of 8 mice. Thus, in this nonoptimal radioimmunotherapy model, significant antitumor responses were preserved using a mildly toxic multiple dosing regimen.
- IT 132572-51-1DP, complexes with 186Re
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and **conjugation** to monoclonal antibody)

- L37 ANSWER 27 OF 42 HCAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1991:117823 HCAPLUS
 DOCUMENT NUMBER: 114:117823
 TITLE: Biodistribution, pharmacokinetic, and imaging studies with rhenium-186-NR-LU-10 whole antibody in LS1741T colonic tumor-bearing mice

AUTHOR(S): Goldrosen, M. H.; Biddle, W. C.; Pancook, J.; Bakshi, S.; Vanderheyden, J. L.; Fritzberg, A. R.; Morgan, A. C., Jr.; Foon, K. A.

CORPORATE SOURCE: Div. Clin. Immunol., Roswell Park Cancer Inst., Buffalo, NY, 14263, USA

SOURCE: Cancer Research (1990), 50(24), 7973-8
CODEN: CNREA8; ISSN: 0008-5472

DOCUMENT TYPE: Journal
LANGUAGE: English

AB Biodistribution, pharmacokinetic, and radioimaging studies were performed with 186Re-labeled NR-LU-10 whole antibody in athymic nude mice bearing the LS174T tumor growing either s.c. or in an exptl. hepatic metastasis model. NR-LU-10 is an IgG2b murine monoclonal antibody (MAb) that reacts with virtually all human tumors of epithelial origin. NR-BC-1, an IgG2b murine MAb that reacts with normal human B-cell and B malignancies, was used as an isotype-matched control. These MAbs were radiolabeled with 186Re (3.7-day phys. half-life; 1.07-MeV .beta.-particle and 137-keV .gamma., 9% abundance) by a preformed chelate approach by using the triamide thiolate ligand system. 186Re-labeled NR-LU-10 (50 .mu.Ci) was injected into nude mice bearing LS174T tumors growing s.c. Biodistribution studies revealed that the LS174T tumor retained the highest concn. of 186Re-labeled NR-LU-10 (5.3% injected dose/g) at day 6. The tumor-to-blood ratio ranged from 0.1:1 to 10.8:1 by day 6, the last day of anal. In contrast, the tumor-to-blood ratio of 186Re-labeled NR-BC-1, the isotype-matched MAb control, was 1:1 on day 6. Pharmacokinetic anal. indicated that the t_{1/2} .beta. of NR-LU-10 for blood and other tissues ranged 21-25 h, whereas the t_{1/2} .beta. for the LS174T tumor averaged 52 h. The area under the curve for tumor compared to blood as 2.8-5.7-fold higher than the area under the curve for all other tissues and organs. The mean residence time for NR-LU-10 in blood and all other organs ranged 23-26 h, whereas the mean residence time for NR-LU-10 in the LS174T tumor was 72 h. Scintigraphic images revealed selective uptake of the 186Re-labeled NR-LU-10, but not of the 186Re-labeled NR-BC-1, at the LS174T tumor site. Studies in an exptl. model of hepatic metastasis revealed a similar selective pattern of 186Re-labeled NR-LU-10 accumulation. Scintigraphic images of the LS174T tumor growing within the athymic nude mouse liver were obtained. The biodistribution, pharmacokinetic, and scintigraphic image results suggest that 186Re-labeled NR-LU-10 shows promise as a therapeutic agent for gastrointestinal cancer.


IT 132572-51-1

RL: PRP (Properties)
(conjugation of, with rhenium-186-Perrhenate)

L37 ANSWER 28 OF 42 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1990:568209 HCAPLUS
DOCUMENT NUMBER: 113:168209
TITLE: Compositions containing technetium-99m-labeled substances and dihydroxybenzenedisulfonate stabilizers for scintigraphy
PATENT ASSIGNEE(S): Solco Basel A.-G., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 11 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 02019328	A2	19900123	JP 1988-159030	19880627

OTHER SOURCE(S): MARPAT 113:168209
GI



AB A medium for e.g. bone scintigraphy contains ^{99m}Tc -labeled substances and stabilizers I ($\text{R} = \text{H}$, sulfonyl, carboxymethyl; $\text{R1} = \text{sulfonyl}$, carboxymethyl) or its salts. I is e.g. 2,5-dihydroxybenzene-1,4-disulfonic acid or its Na salt. Thus, an injection consists of ^{99m}Tc -methylenediphosphonate, SnCl_2 , and K2 2,5-dihydroxybenzene-1,4-disulfonate. The prepn. was stable as detd. by free pertechnetate content.

IT **66516-09-4D**, complexes with **technetium-99m**

RL: BIOL (Biological study)
(scintigraphy with media contg. dihydroxybenzenedisulfonate stabilizers and)

L37 ANSWER 29 OF 42 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1990:568057 HCAPLUS

DOCUMENT NUMBER: 113:168057

TITLE: An investigation of factors that might influence the radiochemical purity and stability of ^{99m}Tc -MAG3

AUTHOR(S): Millar, A. M.; O'Brien, L. M.

CORPORATE SOURCE: R. Infirn., Edinburgh, EH3 9YW, UK

SOURCE: Eur. J. Nucl. Med. (1990), 16(8-10), 615-19

CODEN: EJNMD9; ISSN: 0340-6997

DOCUMENT TYPE: Journal

LANGUAGE: English

AB ^{99m}Tc -mercaptoacetyltriglycine (^{99m}Tc -MAG3) was prepnd. from a com. kit by various techniques to assess the effect of a no. of variables on radiochem. purity and stability. Its radiochem. purity was detd. by HPLC at 0 and 6 h after prepn. and was found to be consistently >95%. It has been demonstrated that the radiochem. purity of ^{99m}Tc -MAG3 prepnd. according to the manufacturer's instructions is not influenced by the vol. of ^{99}Tc generator eluate used, agitation, the presence of air in the reaction vial or the use of a ^{99m}Tc generator eluate with a ^{99}Tc : ^{99m}Tc ratio of 16:1. A modified method of prepn. in which the MAG3 kit is reconstituted with saline before addn. of $[^{99m}\text{Tc}]$ pertechnetate has been shown to yield a satisfactory product and should help to minimize the radiation dose to the fingers of radiopharmacy staff.

IT **66516-09-4DP**, **technetium-99 complexes**

RL: SPN (Synthetic preparation); PREP (Preparation)
(prep. and radiochem. purity and stability of metastable, kidney scintigraphy in relation to)

L37 ANSWER 30 OF 42 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1990:455132 HCAPLUS

DOCUMENT NUMBER: 113:55132

TITLE: Synthesis and animal studies of technetium-99m MAG3 [mercaptoacetylglycylglycylglycine] a renal function imaging agent

AUTHOR(S): Gao, Weizhen; Chen, Fang; Li, Yuping; Wang, Shizhen; Lu, Liyi

CORPORATE SOURCE: PUMC Hosp., Chin. Acad. Med. Sci., Beijing, Peop. Rep.

SOURCE: China
 Hejishu (1990), 13(1), 57-60
 CODEN: NUTEDL; ISSN: 0253-3219
 DOCUMENT TYPE: Journal
 LANGUAGE: Chinese
 AB 99mTc-labeled MAG3 was synthesized based on the method described by A. R. Fritzberg et al. (1986). After i.v. injection, the biodistribution of 99mTc-MAG3 and o-[131I]iodohippurate (OIH) in blood, kidney, liver, stomach, intestine, and urine of mice was detd. Both MAG3 and OIH were excreted mainly via urine, and probenecid treatment reduced MAG3 and OIH excretion in urine. 99mTc-MAG3 and OIH were used successfully for renal imaging of rabbits. 99mTc-MAG3 is potentially useful for replacing 131I-OIH as a renal imaging agent.

IT 66516-09-4D, complexes with technetium-99

RL: BIOL (Biological study)
 (metab. and biodistribution of and scintig. of kidney with)

L37 ANSWER 31 OF 42 HCAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1990:213179 HCAPLUS
 DOCUMENT NUMBER: 112:213179
 TITLE: Different technetium complexes with mercaptoacetyltriglycine
 AUTHOR(S): Johannsen, B.; Noll, B.; Heise, K. H.; May, K.; Spies, H.; Hoffmann, I.; Hoffmann, S.; Kloetzer, D.; Reiss, H.; et al.
 CORPORATE SOURCE: Charite Hosp., Humboldt Univ., Berlin, DDR-1040, Ger. Dem. Rep.
 SOURCE: Isotopenpraxis (1990), 26(3), 97-101
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Various Tc(V) complexes with mercaptoacetylglycylglycylglycine (MAG3) were prep'd. from TcO4- via Tc(V) gluconate or tartrate by redn. with SuCl2 and simultaneous or subsequent reaction of the intermediate with unprotected MAG3. By varying the reaction conditions (pH, reaction time, temp., concns., and molar ratios), 4 complexes (of which 2 were closely related) in addn. to the known Tc(V) oxo complex employed in kidney function tests were obtained. HPLC, thin-layer chromatog., electrophoresis, and UV-vis spectroscopy were employed to characterize the complexes, and biodistribution studies in guinea pigs with the 99mTc derivs. revealed differences in their excretion. The complexes were not unequivocally identified.

IT 66516-09-4DP, technetium-99 complexes

RL: BPR (Biological process); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)
 (prepn. and metab. of, kidney scintigraphy in relation to)

L37 ANSWER 32 OF 42 HCAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1989:610697 HCAPLUS
 DOCUMENT NUMBER: 111:210697
 TITLE: Location of a contact site between actin and myosin in the three-dimensional structure of the acto-S1 complex
 AUTHOR(S): Kasprzak, Andrzej A.; Chaussepied, Patrick; Morales, Manuel F.
 CORPORATE SOURCE: Cardiovasc. Res. Inst., Univ. California, San Francisco, CA, 94143-0524, USA
 SOURCE: Biochemistry (1989), 28(23), 9230-8
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Using fluorescence resonance energy transfer (FRET), distances from chromophores located at or near the actin-binding stretch of amino acids 633-642 of myosin subfragment 1 (S1) to 5 points in the acto-S1 complex

were measured. Specific labeling of this site was achieved by first attaching the desired chromophore to an antipeptide that, by means of its charge complementarity, specifically binds to this segment of S1 and then crosslinking the fluorescent peptide to the protein. According to this technique, antipeptides containing 3 different labels, viz., N-dansylaziridine, (iodoacetamido)fluorescein, and monobromobimane, were purified and covalently bound to S1. A second chromophoric group, required for FRET measurements, was selected in such a way as to provide a good spectral overlap with the corresponding peptide chromophore. Cysteine (Cys)-707 (SH1) and Cys-697 (SH2) on S1 were modified by using iodoacetamido and maleimido derivs. of rhodamine, 1,N6-ethenoadenosine 5'-diphosphate was trapped at the S1 active site with orthovanadate, Cys-374 on actin was modified with either N-[4-[(4-(dimethylamino)phenyl)azo]phenyl]maleimide or N-[[(iodoacetyl)amino]ethyl]-5-naphthylamthene analog. By use of excited-state lifetime fluorometry, the following distances from the stretch 633-642 of S1 to other points on S1 or actin were measured: Cys-707 (S1), 50.3 .ANG.; Cys-697 (S1), 49.4 .ANG.; active site of S1, .gtreq.44 .ANG., nucleotide binding site (actin), .gtreq.41.4 ; and Cys-374 (actin), .apprx.53 .ANG.. Addn. of MgATP had a small effect on the distance between the peptide and Cys-707, increasing it by .apprx.2%, whereas it had a more pronounced effect on the distance between the peptide and Cys-697, where an increase of 14% was obsd. The effect of actin on these 2 distances was negligible. These data enabled one (1) to place for the first time an interprotein contact in the 3-dimensional map of the acto-S1 complex, (2) to definitively exclude models of communication between the nucleotide and actin binding sites in S1 that involve direct contact or close proximity of these 2 loci of S1, and (3) detect intraprotein motion in S1 induced by binding of MgATP to the protein.

IT 118407-76-4DP, derivs., myosin subfragment 1 **conjugates**

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

L37 ANSWER 33 OF 42 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1989:570213 HCAPLUS
DOCUMENT NUMBER: 111:170213
TITLE: Comparison of technetium-99m-MAGAG-DA and
technetium-99m-MAG3 in human volunteers
AUTHOR(S): Verbruggen, A.; Bormans, G.; Vandecruys, A.;
Verhaegen, L.; Devos, P.; De Roo, M.
CORPORATE SOURCE: Univ. Hosp. Gasthuisberg, Louvain, B-3000, Belg.
SOURCE: Nuklearmedizin, Suppl. (Stuttgart) (1989), 25(Trends
Possibilities Nucl. Med.), 440-2
CODEN: NMBSAG; ISSN: 0550-3175

DOCUMENT TYPE: Journal
LANGUAGE: English

AB The renal imaging agents 99mTc-mercaptoacetyltriglycine (MAG3) and 99mTc-mercaptoacetylglucyl-D-alanylglutamine (MAGAG-DA) were compared in human volunteers. 99mTc-MAGAG-DA gave a superior renogram due to its higher plasma clearance, higher urinary excretion, lower retention in liver, and shorter time to renal max. However, it was less practical for routine work because it requires an HPLC purifn. step.

IT 66516-09-4D, complexes with **technetium-99**

RL: BIOL (Biological study)
(scintigraphy with, of kidney, **technetium-99m-mercaptoacetylglucylalanylglutamine** comparison with)

L37 ANSWER 34 OF 42 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1989:570212 HCAPLUS
DOCUMENT NUMBER: 111:170212
TITLE: Separation of the enantiomers of technetium-99m-MAG3
and their renal excretion in baboons and a volunteer
AUTHOR(S): Verbruggen, A.; Bormans, G.; Cleynhens, B.;

CORPORATE SOURCE: Hoogmartens, M.; Vandecruys, A.; De Roo, M.
 SOURCE: Univ. Hosp. Gasthuisberg, Louvain, B-3000, Belg.
 Nuklearmedizin, Suppl. (Stuttgart) (1989), 25(Trends
 Possibilities Nucl. Med.), 436-9
 CODEN: NMBSAG; ISSN: 0550-3175

DOCUMENT TYPE: Journal
 LANGUAGE: English

AB The renal tubular system has shown high stereospecificity for Me derivs. of technetium-99m-mercaptoacetyltriglycine (MAG3). It was thus of interest to develop a method to sep. isomers and compare their renal excretion characteristics. The enantiomers were first converted to diastereomeric ester derivs. and sep'd. by reverse phase HPLC, followed by removal of the ester functional group. Plasma clearance, renal max. and excretion, and liver retention of the SA and SB enantiomers were compared. Plasma clearance of the SB enantiomer was slightly higher (20%) and the SA enantiomer retention by liver was more pronounced. However, there were insufficient differences between the enantiomers to justify their use over that of the racemic mixt. for renal function studies.

IT 66516-09-4D, complexes with **technetium-99**

RL: BIOL (Biological study)
 (enantiomeric resln. and pharmacokinetics of, kidney scintigraphy in relation to)

IT 123228-58-ODP, complex with **technetium-99**

RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and isomeric resln. and deprotection of)

L37 ANSWER 35 OF 42 HCPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1989:453446 HCPLUS

DOCUMENT NUMBER: 111:53446

TITLE: Metal-radionuclide-labeled proteins and glycoproteins and their preparation for diagnosis and therapy

INVENTOR(S): Fritzberg, Alan R.; Kasina, Sudhakar; Vanderheyden, Jean Luc; Srinivasan, Ananthachari

PATENT ASSIGNEE(S): NeoRx Corp., USA

SOURCE: Eur. Pat. Appl., 20 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 284071	A2	19880928	EP 1988-104755	19880324
EP 284071	A3	19900516		
EP 284071	B1	19940608		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
AT 106898	E	19940615	AT 1988-104755	19880324
DK 8801654	A	19880927	DK 1988-1654	19880325
NO 8801332	A	19880927	NO 1988-1332	19880325
AU 8813751	A1	19880929	AU 1988-13751	19880325
AU 619738	B2	19920206		
CN 1034545	A	19890809	CN 1988-102772	19880325
CA 1328147	A1	19940329	CA 1988-562452	19880325
JP 01019058	A2	19890123	JP 1988-70902	19880326
PRIORITY APPLN. INFO.: US 1987-31440 19870326				
			EP 1988-104755	19880324

OTHER SOURCE(S): MARPAT 111:53446

GI



AB Metal thiotriaza chelating compds. I [$T = H$, S protecting group; $X = H_2, O$; $R = H$, nonalkyl amino acid side chain (.noteq. cysteine), alkyl, geminal dialkyl, $(CH_2)_nZ$; $Z = CO_2H$, conjugation group, targeting compd.; $n = 1-4$; $R_1 = H_2, (CH_2)_nZ$, polar group(s) substituted alkyl; where the compd. has .gtoreq.1 $(CH_2)_nZ$ group] and chelates II ($M = \text{radionuclide}$; the rest as above) are prep'd. and conjugated to proteins, glycoproteins, carbohydrates, or their fragments for use in diagnosis and therapy. Gly-Gly-Gly was reacted with benzoyl-protected thioglycolic acid succinimidate ester. The product was treated with ^{99m}Tc -pertechnetate to give 90-95% ^{99m}Tc -mercapto-Gly-Gly-Gly. The complex was esterified with 2,3,5,6-tetrafluorophenol and the ester was conjugated with antimelanoma IgG. Nude mice bearing melanoma xenographs were injected with the labeled conjugate. After 20 h the tumor had the highest percentage dose per g tissue. Low liver and spleen concns. (0.26, each) indicated good excretion patterns. Low stomach levels (0.23) indicated high stability, since loss of ^{99m}Tc as pertechnetate is seen as relatively high levels of radioactivity in stomach tissue.

IT **121557-57-1DP, technetium-99 complexes**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and reaction of, with antimelanoma IgG)

IT **66516-09-4DP, technetium-99 complexes, antimelanoma IgG conjugates**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and reaction of, with tetrafluorophenol, melanoma targeting by)

L37 ANSWER 36 OF 42 HCPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1989:53848 HCPLUS

DOCUMENT NUMBER: 110:53848

TITLE: Comparison of technetium-99m-labeled MAG3 kit with HPLC-purified technetium-99m-labeled MAG3 and OIH in rats

AUTHOR(S): Coveney, Joseph R.; Robbins, Mark S.

CORPORATE SOURCE: Mallinckrodt, Inc., Hazelwood, MO, 63042, USA

SOURCE: J. Nucl. Med. (1987), 28(12), 1881-7

CODEN: JNMEAQ; ISSN: 0022-3123

DOCUMENT TYPE: Journal

LANGUAGE: English

AB ^{99m}Tc -mercaptoacetylglycylglycylglycine (MAG3) in high (.gtoreq.95%) radiochem. purity is prep'd. from lyophilized kits contg. benzoylMAG3, Na tartrate, lactose, and stannous chloride by adding Na $[^{99m}\text{Tc}]$ pertechnetate and heating the contents briefly. Const.-infusion renal whole-blood clearance obtained with ^{99m}Tc -MAG3 kits was compared with that obtained with HPLC pure ^{99m}Tc -MAG3, and with co-infused $[^{131}\text{I}]$ iodohippurate (OIH) in anesthetized rats. Av. renal whole-blood clearance of $[^{99m}\text{Tc}]$ MAG3 from kits wa 3.9 mL/min/100 body wt. (mean) and that for HPLC-pure ^{99m}Tc -MAG3 was 4.6. Renal whole blood clearance ratios for ^{99m}Tc -MAG3 to co-infused $[^{131}\text{I}]$ OIH were for both kit formulation (1.7) and HPLC-pure ^{99m}Tc -MAG3 (1.9). Differences in these 2 measures were not significant. Plasma binding (detd. from blood drawn at the end of the infusion) of ^{99m}Tc -MAG3 prep'd. from both kits (75%) and HPLC-sepn. (76%) were greater than that of $[^{131}\text{I}]$ OIH in corresponding plasma samples (31 and 32%, resp.). Renograms

performed in anesthetized rats revealed no differences between kit-prepd. ^{99m}Tc -MAG3 and $[^{131}\text{I}]$ OIH in terms of time-to-peak renal activity (5.0 and 2.2 min, mean for ^{99m}Tc -MAG3 and $[^{131}\text{I}]$ OIH, resp.), in terms of time to fall to half-maximal activity (15.3 and 9.6 min, resp.), or in terms of fraction of peak radioactivity in right kidney (0.53 for both substances). To assess possible interference from hepatobiliary uptake and excretion in renal failure, radioactivity in liver regions of interest was followed by gamma camera scintigraphy for 30 min after i.v. injection of $[^{131}\text{I}]$ OIH and kit and HPLC-purified ^{99m}Tc -MAG3 in anesthetized rats rendered anephric by ligating renal peduncles. Liver activity was 25% of total for both preps. of ^{99m}Tc -MAG3 and was 22% of total for $[^{131}\text{I}]$ OIH. There were no differences among the substances.

IT 66516-09-4D, technetium-99 complexes

RL: BIOL (Biological study)

(metab. of and scintigraphy of kidney with, kit preps. evaluation for)

L37 ANSWER 37 OF 42 HCPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1988:586394 HCPLUS

DOCUMENT NUMBER: 109:186394

TITLE: Synthesis, radiochromatography and biodistribution of technetium-99m-mercaptoacetyltriglycine-technetium(V) ($\text{Tc}^{99m}\text{-MAtG}$)

AUTHOR(S): Angelberger, Peter; Buchheit, Otto; Fally, Friedrich; Egger, Martin

CORPORATE SOURCE: Inst. Chem., Oesterr. Forschungszent. Seibersdorf G.m.b.H., Seibersdorf, A-2444, Austria

SOURCE: Oesterr. Forschungszent. Seibersdorf, [Ber.] OEFZS (1987), OEFZS-4428, 9 pp.

CODEN: OFSODK; ISSN: 0253-5270

DOCUMENT TYPE: Report

LANGUAGE: English

AB As the latest in a series of Tc^{99m} -complexes, ^{99m}Tc -MAtG was recently suggested as replacement for ^{123}I -o-iodohippuric acid (^{123}I -oIHA) with specificity for the renal excretion pathway. In an optimization study the S-benzoyl protected ligand was synthesized in a 3 step sequence starting from mercaptoacetic acid and using peptide chem. methodol. The complex with a Tc(V)=O core was prepd. by dithionite redn. of n.c.a. ^{99m}Tc -TcO₄⁻ and purified from side-products by preparative HPLC. Product radiochem. purity was typically better than >98% by TLC and remained stable over 24 h. Biodistribution in mice demonstrated fast and specific renal excretion and clin. diagnostic results were equiv. to ^{123}I -oIHA.

IT 66516-09-4DP, technetium 99 complexes

RL: BOC (Biological occurrence); SPN (Synthetic preparation); BIOL

(Biological study); OCCU (Occurrence); PREP (Preparation)

(prepn. and biodistribution of)

L37 ANSWER 38 OF 42 HCPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1988:545393 HCPLUS

DOCUMENT NUMBER: 109:145393

TITLE: Biodistribution of complex impurities and steady state clearance of technetium-99m-MAG3

AUTHOR(S): Brandau, W.; Bubeck, B.; Eisenhut, M.; Taylor, D. M.

CORPORATE SOURCE: Dep. Nucl. Med., Univ. Heidelberg, Heidelberg, Fed. Rep. Ger.

SOURCE: Nuklearmedizin, Suppl. (Stuttgart) (1988), 24, 748-52

CODEN: NMBSAG; ISSN: 0550-3175

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The prepn., biodistribution in female Sprague-Dawley rats and humans, and scintigraphy in rats of ^{99m}Tc -MAG3 (mercaptoacetyltriglycine) were examd., using kit-prepd. and HPLC-purified ^{99m}Tc -MAG3 preps. Scintiphotos in rats revealed that impurities B, C, and D must be excluded from ^{99m}Tc -MAG3 kit preps. for renal imaging due to their high hepatobiliary excretion

whereas impurity A seems tolerable for kidney imaging. For HPLC-purified ^{99m}Tc -MAG3, its renal tubular excretion rate was only 67% of that of $\text{o-[}^{131}\text{I}]$ iodohippurate (OIH) in humans. The results indicate that ^{99m}Tc -MAG3 may be a useful agent for renal function studies, possibly replacing radioiodinated OIH.

IT 66516-09-4DP, complexes with **technetium-99**

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and metab. of and scintigraphy of kidney with)

L37 ANSWER 39 OF 42 HCPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1988:182862 HCPLUS

DOCUMENT NUMBER: 108:182862

TITLE: Animal evaluation of technetium-99m triamide

mercaptide complexes as potential renal imaging agents
Eshima, Dennis; Taylor, Andrew, Jr.; Fritzberg, Alan

R.; Kasina, Sudhakar; Hansen, Lory; Sorenson, James F.
Dep. Radiol., Univ. Utah, Salt Lake City, UT, USA


SOURCE: J. Nucl. Med. (1987), 28(7), 1180-6

CODEN: JNMEAQ; ISSN: 0022-3123

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



AB ^{99m}Tc mercaptoacetylglycylglycylglycine (MAG3), a ^{99m}Tc triamide mercaptide (N3S) [I, where R = CH_2COOH , $\text{CH}_2\text{CONHCH}_2\text{COOH}$, $\text{CH}(\text{CH}_3)\text{COOH}$, $\text{CH}(\text{CH}_2\text{C}_6\text{H}_5)\text{COOH}$, $\text{CH}(\text{COOH})\text{CH}_2\text{COOH}$, $\text{CH}(\text{COOH})\text{CH}_2\text{CONH}_2$, $\text{CH}(\text{COOH})\text{CH}_2\text{CH}_2\text{COOH}$, $\text{CH}(\text{COOH})\text{CH}_2\text{CH}_2\text{CONH}_2$] compd., has been synthesized in an attempt to obviate the stereochem. problems assocd. with the diamide dimercaptide (N2S2) ligands. Because initial studies have been promising, the terminal glycine on the MAG3 compd. has been varied to create a new series of N3S compds. Twelve new N3S complexes were initially screened in mice and the more promising complexes, ^{99m}Tc -MAG3, ^{99m}Tc mercaptoacetylglycylglycyl-L-alanine, ^{99m}Tc mercaptoacetylglycylglycyl-L-asparagine, and ^{99m}Tc mercaptoacetylglycylglycyl-L-glutamine, were further evaluated in rats utilizing const. infusion blood clearances, extn. efficiencies, and protein binding assays. The renal excretion of all these complexes compared favorably with simultaneously administered $[^{131}\text{I}]$ iodohippurate and $[^{125}\text{I}]$ iothalamate. The triamide mercaptide complexes represent a new ligand class for ^{99m}Tc , which may provide a variety of complexes for the evaluation of renal tubular function.

IT 66516-09-4 114115-72-9 114115-73-0

114115-74-1 114115-75-2 114115-76-3

114115-77-4 114115-78-5

RL: BIOL (Biological study)

(**radiolabeling** of, with **technetium-99m**)

L37 ANSWER 40 OF 42 HCPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1988:163498 HCPLUS

DOCUMENT NUMBER: 108:163498

TITLE: Characterization of prion proteins with monospecific antisera to synthetic peptides

AUTHOR(S): Barry, Ronald A.; Vincent, Marion T.; Kent, Stephen B.

CORPORATE SOURCE: H.; Hood, Leroy E.; Prusiner, Stanley B.
 Dep. Neurol., Univ. California, San Francisco, CA,
 94143, USA

SOURCE: J. Immunol. (1988), 140(4), 1188-93
 CODEN: JOIMA3; ISSN: 0022-1767

DOCUMENT TYPE: Journal
 LANGUAGE: English

AB The prion protein (PrP) 27-30 is the major macromol. component in highly purified prepns. of prions derived from scrapie-infected hamster brain. Immunoblotting studies demonstrated that this protein is generated by partial protease digestion of a larger precursor (PrPSc) with an apparent mol. wt. of 33-35 kilodaltons, and that a protease-sensitive cellular-PrP isoform, designated PrPC, is present in normal hamster brain. To characterize the relationships among these proteins, ELISA and immunoblotting studies were undertaken with rabbit antisera raised against 3 synthetic PrP peptides. All 3 antisera specifically reacted with the prion proteins, and failed to identify other lower or higher mol. wt. PrP proteins. Thus, the primary structures of PrP 27-30, PrPSc, and PrPC are related; this conclusion supports mol. cloning studies indicating that these proteins are encoded by the same chromosomal gene.

IT 113944-83-5DP, protein conjugates 113944-84-6DP
 , protein conjugates 113960-59-1DP, protein conjugates

RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepns. and antisera to, for prion protein characterization)

L37 ANSWER 41 OF 42 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1987:400968 HCAPLUS
 DOCUMENT NUMBER: 107:968

TITLE: Computer-aided design and physiological testing of a luteinizing hormone-releasing hormone analog for 'adjuvant-free' immunocastration

AUTHOR(S): Morrison, Christopher A.; Fishleigh, Robert V.; Ward, David J.; Robson, Barry

CORPORATE SOURCE: Dep. Cell. Struct. Biol., Univ. Oxford, Manchester, M13 9PT, UK

SOURCE: FEBS Lett. (1987), 214(1), 65-70
 CODEN: FEBLAL; ISSN: 0014-5793

DOCUMENT TYPE: Journal
 LANGUAGE: English

AB An analog of LH-RH (LH-RH-Gly-Cys-OH) contg. an extension of Gly-Cys at the C-terminus was designed to permit reproducible coupling to a suitably modified carrier via a thioether bond. Potential energy calcns. indicated that this analog adopted a conformation in soln. virtually identical to the type II turn around Gly-6-Leu-7 predicted for native LH-RH. Intradermal administration of a conjugate of this analog with purified protein deriv. of tuberculin to male rats previously primed with BCG vaccine rapidly led to complete testicular regression. This adjuvant-free immunization protocol may represent an alternative to castration for the veterinary control of reproductive function.

IT 108635-48-9D, tuberculin conjugates

RL: BIOL (Biological study)
 (for immunocastration)

L37 ANSWER 42 OF 42 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1987:117762 HCAPLUS
 DOCUMENT NUMBER: 106:117762

TITLE: Human kappa light chain subgroup analysis with synthetic peptide-induced antisera

AUTHOR(S): Silverman, Gregg J.; Carson, Dennis A.; Solomon, Alan; Fong, Sherman

CORPORATE SOURCE: Dep. Basic Clin. Res., Scripps Clin. Res. Found., La Jolla, CA, 92037, USA

SOURCE: J. Immunol. Methods (1986), 95(2), 249-57
CODEN: JIMMBG; ISSN: 0022-1759

DOCUMENT TYPE: Journal
LANGUAGE: English

AB To create anti-human Ig .kappa. subgroup antibodies with predefined specificity, rabbits were immunized with synthetic peptides which correspond to sequences within the first framework region of prototype .kappa. I, II, III, and IV light chains. The peptide-induced antisera recognized primary sequence-dependent .kappa. subgroup determinants. They correctly predicted the amino acid sequence in the first framework region of 2 .kappa. light chains. By Western immunoblotting and enzyme-linked immunoassay the antisera also identified previously typed, monoclonal light chains of different subgroups with complete specificity. These reagents define a site of .kappa. subgroup distinction and represent a potent tool for the characterization of light chain heterogeneity.

IT 107140-42-1DP, hemocyanin conjugates

RL: PREP (Preparation)

(prepn. of, and Ig kappa light chain-specific antibodies induction by, of human)

=>
=>

=> select hit rn 137 1-42
E1 THROUGH E30 ASSIGNED

=> fil reg
FILE 'REGISTRY' ENTERED AT 15:14:53 ON 11 OCT 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 10 OCT 2002 HIGHEST RN 460706-73-4
DICTIONARY FILE UPDATES: 10 OCT 2002 HIGHEST RN 460706-73-4

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>


=>
=>
=> d his 138

(FILE 'HCAPLUS' ENTERED AT 15:14:10 ON 11 OCT 2002)
SELECT HIT RN L37 1-42

FILE 'REGISTRY' ENTERED AT 15:14:53 ON 11 OCT 2002
L38 30 S E1-E30

=> d ide can 138 1-30

L38 ANSWER 1 OF 30 REGISTRY COPYRIGHT 2002 ACS
 RN **154150-09-1** REGISTRY
 CN Glycine, N-[N-[N-(mercaptoacetyl)glycyl]glycyl]-, methyl ester (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C9 H15 N3 O5 S
 SR CA
 LC STN Files: CA, CAPLUS




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 120:259847

L38 ANSWER 2 OF 30 REGISTRY COPYRIGHT 2002 ACS
 RN **154150-08-0** REGISTRY
 CN Glycine, N-(mercaptoacetyl)glycyl-, methyl ester (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Glycine, N-[N-(mercaptoacetyl)glycyl]-, methyl ester
 FS 3D CONCORD
 MF C7 H12 N2 O4 S
 SR CA
 LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 2 REFERENCES IN FILE CAPLUS (1962 TO DATE)


REFERENCE 1: 127:28218

REFERENCE 2: 120:259847

L38 ANSWER 3 OF 30 REGISTRY COPYRIGHT 2002 ACS
 RN **146509-03-7** REGISTRY
 CN L-Cysteine, N-[N-[N-[1-[N2-[N2-[N2-[N2-(N-glycylglycyl)-L-lysyl]-L-arginyl]-L-lysyl]-L-lysyl]-L-lysyl]-L-prolyl]glycyl]glycyl]- (9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 MF C46 H86 N18 O12 S
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B

CO_2H

PAGE 2-A



PAGE 2-B



1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 118:141585

L38 ANSWER 4 OF 30 REGISTRY COPYRIGHT 2002 ACS

RN 144269-59-0 REGISTRY

CN L-Cysteine, N2,N6-bis(1-deoxy-4-O-.beta.-D-galactopyranosyl-D-glucitol-1-yl)-L-lysyl-N6-[N2,N6-bis(1-deoxy-4-O-.beta.-D-galactopyranosyl-D-glucitol-1-yl)-L-lysyl]-L-lysylglycyl-L-serylglycylglycyl-L-serylglycylglycyl-L-serylglycylglycyl- (9CI) (CA INDEX NAME)

FS PROTEIN SEQUENCE


MF C92 H167 N17 O58 S

SR CA


LC STN Files: CA, CAPLUS

RELATED SEQUENCES AVAILABLE WITH SEQLINK



PAGE 1-A



PAGE 1-B



PAGE 1-C




- 1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 117:227232


L38 ANSWER 5 OF 30 REGISTRY COPYRIGHT 2002 ACS
 RN 143090-39-5 REGISTRY
 CN L-Cysteine, N-[N-[N-[N-[N6-[(9H-fluoren-9-ylmethoxy)carbonyl]-N2-[N-[N6-[(9H-fluoren-9-ylmethoxy)carbonyl]-N2-(N-L-.alpha.-glutamyl-L-.alpha.-glutamyl)-L-lysyl]glycyl]-L-lysyl]-L-.alpha.-glutamyl]glycyl]-L-lysyl]- (9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 MF C71 H88 N12 O23 S
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 117:118497

L38 ANSWER 6 OF 30 REGISTRY COPYRIGHT 2002 ACS
 RN 143090-38-4 REGISTRY
 CN L-Cysteine, N-[N-[N-[N2-[N2-L-.alpha.-aspartyl-N6-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-lysyl]glycyl]-N6-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-lysyl]-L-.alpha.-aspartyl]glycyl]glycyl]- (9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH


MF C59 H70 N10 O17 S

SR CA


LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)


REFERENCE 1: 117:118497

L38 ANSWER 7 OF 30 REGISTRY COPYRIGHT 2002 ACS
 RN 143090-37-3 REGISTRY


CN L-Cysteine, N-[N-[N-[N6-[(9H-fluoren-9-ylmethoxy)carbonyl]-N2-[N-[N6-[(9H-fluoren-9-ylmethoxy)carbonyl]-N2-L-.alpha.-glutamyl-L-lysyl]glycyl]-L-lysyl]-L-.alpha.-glutamylglycyl]glycyl]- (9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 MF C61 H74 N10 O17 S
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 117:118497

L38 ANSWER 8 OF 30 REGISTRY COPYRIGHT 2002 ACS

RN 142770-36-3 REGISTRY

CN L-Cysteine, L-threonyl-L-tyrosyl-L-seryl-L-seryl-L-prolyl-L-.alpha.-glutamyl-L-.alpha.-aspartylglycyl-L-isoleucyl-L-histidyl-L-.alpha.-glutamyl-L-leucyl-L-phenylalanyl-L-prolyl-L-alanyl-L-prolyl-L-.alpha.-aspartylglycyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-aspartyl-L-threonyl-L-alanyl-L-.alpha.-glutamyl-L-leucyl-L-glutaminylglycylglycyl-(9CI) (CA INDEX NAME)

FS PROTEIN SEQUENCE; STEREOSEARCH


MF C130 H190 N32 O52 S

SR CA


LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B




PAGE 1-C




PAGE 2-A



PAGE 2-B



PAGE 3-A




- 1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 117:107807

L38 ANSWER 9 OF 30 REGISTRY COPYRIGHT 2002 ACS
 RN 135236-49-6 REGISTRY
 CN L-Cysteine, L-lysyl-L-methionyl-L-valyl-L-.alpha.-glutamyl-L-asparaginyl-L-alanyl-L-lysyl-L-.alpha.-aspartyl-L-.alpha.-glutamyl-L-valyl-L-.alpha.-glutamyl-L-lysyl-L-.alpha.-glutamyl-L-leucylglycyl-L-lysyl-L-arginylglycyl-L-threonyl-L-arginylglycylglycyl- (9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 MF C103 H180 N34 O36 S2
 SR CA
 LC STN Files: CA, CAPLUS

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B

Bu-i


PAGE 2-A




PAGE 2-B



PAGE 3-A




PAGE 3-B



1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 115:99411

L38 ANSWER 10 OF 30 REGISTRY COPYRIGHT 2002 ACS
RN **132572-51-1** REGISTRY
CN Glycinamide, N-(mercaptoacetyl)glycyl-N-[4-oxo-4-(2,3,5,6-tetrafluorophenoxy)butyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C16 H17 F4 N3 O5 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


2 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 114:139080


REFERENCE 2: 114:117823

L38 ANSWER 11 OF 30 REGISTRY COPYRIGHT 2002 ACS
RN **131400-08-3** REGISTRY
CN L-Leucinamide, L-cysteinylglycylglycylglycyl-L-lysyl-L-.alpha.-glutamyl-L-lysylglycyl-L-histidyl-L-tryptophyl-L-alanyl-L-lysyl-L-.alpha.-aspartyl-L-cysteinyl-L-prolyl-L-lysyl-L-lysyl-L-prolyl-L-arginylglycyl-L-prolyl-L-arginylglycyl-L-prolyl-L-arginyl-L-glutaminyl-L-threonyl-L-seryl-L-leucyl- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C139 H231 N49 O37 S2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PAGE 1-A





PAGE 1-B




O


PAGE 2-A





PAGE 2-B



PAGE 3-A



PAGE 3-B




- 1 REFERENCES IN FILE CA (1962 TO DATE)
- 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
- 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 115:778


L38 ANSWER 12 OF 30 REGISTRY COPYRIGHT 2002 ACS
 RN 131400-07-2 REGISTRY
 CN L-Alaninamide, L-cysteinylglycylglycylglycyl-L-arginyl-L-arginyl-L-
 arginyl-L-arginyl-L-tyrosyl-L-arginyl-L-arginyl-L-seryl-L-threonyl-L-valyl-
 (9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 MF C71 H127 N35 O19 S
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B



PAGE 2-A



PAGE 2-B




- 1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 115:778


L38 ANSWER 13 OF 30 REGISTRY COPYRIGHT 2002 ACS
 RN 131399-96-7 REGISTRY
 CN L-Threonine, L-cysteinylglycylglycyl-L-phenylalanyl-L-phenylalanylglycyl-L-alanyl-L-valyl-L-isoleucylglycyl-L-threonyl-L-isoleucyl-L-alanyl-L-leucylglycyl-L-valyl-L-alanyl-L-threonyl-L-alanyl-L-threonyl-L-alanyl-L-alanyl-L-glutaminyl-L-isoleucyl- (9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 MF C104 H168 N26 O31 S
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 1-C




PAGE 1-D



PAGE 2-C



PAGE 2-D




- 1 REFERENCES IN FILE CA (1962 TO DATE)
- 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
- 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 115:778

L38 ANSWER 14 OF 30 REGISTRY COPYRIGHT 2002 ACS
 RN 123228-58-0 REGISTRY
 CN Glycine, N-[N-[N-(mercaptoacetyl)glycyl]glycyl]-, 1-methylpropyl ester,
 (S)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C12 H21 N3 O5 S
 SR CA
 LC STN Files: CA, CAPLUS

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 1 REFERENCES IN FILE CA (1962 TO DATE)
- 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
- 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 111:170212

L38 ANSWER 15 OF 30 REGISTRY COPYRIGHT 2002 ACS
 RN 121557-57-1 REGISTRY
 CN Glycine, N-[N-[N-(mercaptoacetyl)glycyl]glycyl]-, 2,3,5,6-tetrafluorophenyl ester (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C14 H13 F4 N3 O5 S

SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 111:53446

L38 ANSWER 16 OF 30 REGISTRY COPYRIGHT 2002 ACS

RN 118407-76-4 REGISTRY

CN Glycine, N-[N-[N-[N-[N-[N-(N-L-cysteinylglycyl)glycyl]-L-.alpha.-aspartyl]-L-.alpha.-aspartyl]glycyl]glycyl-L-.alpha.-aspartyl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)

FS PROTEIN SEQUENCE; STEREOSEARCH


MF C33 H47 N11 O22 S

SR CA


LC STN Files: CA, CAPLUS

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




2 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 111:210697

REFERENCE 2: 110:53177

L38 ANSWER 17 OF 30 REGISTRY COPYRIGHT 2002 ACS
 RN **114115-78-5** REGISTRY
 CN L-Glutamine, N2-[N-[N-(mercaptoacetyl)glycyl]glycyl]- (9CI) (CA INDEX
 NAME)
 FS STEREOSEARCH
 MF C11 H18 N4 O6 S
 SR CA
 LC STN Files: CA, CAPLUS

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 108:182862

L38 ANSWER 18 OF 30 REGISTRY COPYRIGHT 2002 ACS
 RN **114115-77-4** REGISTRY
 CN L-Glutamic acid, N-[N-[N-(mercaptoacetyl)glycyl]glycyl]- (9CI) (CA INDEX
 NAME)
 FS STEREOSEARCH
 MF C11 H17 N3 O7 S
 SR CA
 LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1962 TO DATE)

1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 108:182862

L38 ANSWER 19 OF 30 REGISTRY COPYRIGHT 2002 ACS
 RN **114115-76-3** REGISTRY
 CN L-Asparagine, N2-[N-[N-(mercaptoproacetyl)glycyl]glycyl]- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C10 H16 N4 O6 S
 SR CA
 LC STN Files: CA, CAPLUS

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 108:182862

L38 ANSWER 20 OF 30 REGISTRY COPYRIGHT 2002 ACS
 RN **114115-75-2** REGISTRY
 CN L-Aspartic acid, N-[N-[N-(mercaptoproacetyl)glycyl]glycyl]- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C10 H15 N3 O7 S
 SR CA
 LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 108:182862

L38 ANSWER 21 OF 30 REGISTRY COPYRIGHT 2002 ACS
 RN **114115-74-1** REGISTRY
 CN L-Phenylalanine, N-[N-[N-(mercaptoproacetyl)glycyl]glycyl]- (9CI) (CA INDEX NAME)

NAME)
 FS STEREOSEARCH
 MF C15 H19 N3 O5 S
 SR CA
 LC STN Files: CA, CAPLUS

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 108:182862

L38 ANSWER 22 OF 30 REGISTRY COPYRIGHT 2002 ACS
 RN 114115-73-0 REGISTRY
 CN L-Alanine, N-[N-[N-(mercaptopropanoyl)glycyl]glycyl]- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C9 H15 N3 O5 S
 SR CA
 LC STN Files: CA, CAPLUS

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 108:182862

L38 ANSWER 23 OF 30 REGISTRY COPYRIGHT 2002 ACS
 RN 114115-72-9 REGISTRY
 CN Glycine, N-[N-[N-[N-(mercaptopropanoyl)glycyl]glycyl]glycyl]- (9CI) (CA INDEX NAME)
 FS 3D CONCORD; PROTEIN SEQUENCE
 MF C10 H16 N4 O6 S
 SR CA
 LC STN Files: CA, CAPLUS

RELATED SEQUENCES AVAILABLE WITH SEQLINK




1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 108:182862


L38 ANSWER 24 OF 30 REGISTRY COPYRIGHT 2002 ACS
 RN **113960-59-1** REGISTRY
 CN L-Alanine, L-cysteinylglycylglycyl-L-lysyl-L-.alpha.-glutamyl-L-seryl-L-glutaminyl-L-alanyl-L-tyrosyl-L-tyrosyl-L-.alpha.-aspartylglycyl-L-arginyl-L-arginyl-L-seryl-L-seryl- (9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 MF C74 H115 N25 O28 S
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A




- 1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 108:163498


L38 ANSWER 25 OF 30 REGISTRY COPYRIGHT 2002 ACS
 RN 113944-84-6 REGISTRY
 CN L-Cysteine, L-methionyl-L-tryptophyl-L-threonyl-L-.alpha.-aspartyl-L-valylglycyl-L-leucyl-L-cysteinyl-L-lysyl-L-lysyl-L-arginyl-L-prolyl-L-lysyl-L-prolylglycylglycyl-L-tryptophyl-L-asparaginyl-L-threonylglycylglycyl-L-seryl-L-arginyl-L-tyrosyl-L-prolylglycylglycyl-(9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 MF C131 H202 N40 O36 S3
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B




PAGE 1-C



PAGE 1-D



PAGE 1-E




- 1 REFERENCES IN FILE CA (1962 TO DATE)
- 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
- 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)


REFERENCE 1: 108:163498

L38 ANSWER 26 OF 30 REGISTRY COPYRIGHT 2002 ACS
 RN 113944-83-5 REGISTRY
 CN L-Cysteine, glycyl-L-glutaminylglycylglycylglycyl-L-threonyl-L-histidyl-L-asparaginyl-L-glutaminyl-L-tryptophyl-L-asparaginyl-L-lysyl-L-prolylglycylglycyl- (9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 MF C65 H96 N24 O22 S
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.

PAGE 1-A






1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 108:163498


L38 ANSWER 27 OF 30 REGISTRY COPYRIGHT 2002 ACS
 RN **108635-48-9** REGISTRY
 CN Luteinizing hormone-releasing factor (swine), 10a-glycine-10b-L-cysteine-
 (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Luteinizing hormone-releasing factor (pig), 10a-glycine-10b-L-cysteine-
 OTHER NAMES:
 CN LH-RH-Gly-Cys
 FS PROTEIN SEQUENCE; STEREOSEARCH
 MF C60 H82 N18 O16 S
 SR CA
 LC STN Files: ADISNEWS, AGRICOLA, BIOSIS, CA, CAPLUS, CIN, PROMT,
 TOXCENTER, USPATFULL

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



9 REFERENCES IN FILE CA (1962 TO DATE)

8 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

9 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 129:240143

REFERENCE 2: 127:288362

REFERENCE 3: 126:181554

REFERENCE 4: 125:298945

REFERENCE 5: 123:306747

REFERENCE 6: 121:246704

REFERENCE 7: 120:132349


REFERENCE 8: 110:226143

REFERENCE 9: 107:968


L38 ANSWER 28 OF 30 REGISTRY COPYRIGHT 2002 ACS
 RN 107140-42-1 REGISTRY
 CN L-Cysteine, L-threonyl-L-glutaminyl-L-seryl-L-prolyl-L-leucyl-L-seryl-L-leucyl-L-prolyl-L-valyl-L-threonyl-L-prolylglycylglycyl- (9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 MF C58 H97 N15 O20 S
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 106:117762

L38 ANSWER 29 OF 30 REGISTRY COPYRIGHT 2002 ACS
 RN **66516-09-4** REGISTRY
 CN Glycine, N-(mercaptoacetyl)glycylglycyl- (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Glycine, N-[N-[N-(mercaptoacetyl)glycyl]glycyl]-
 OTHER NAMES:
 CN MAG 3
 CN Mercaptoacetylglycylglycylglycine
 CN Mercaptoacetyltriglycine
 CN Mertiatide
 FS 3D CONCORD
 MF C8 H13 N3 O5 S
 LC STN Files: AGRICOLA, BIOPHARMA, BIOSIS, BIOTECHNO, CA, CAPLUS, CIN,
 DDFU, DIOGENES, DRUGU, DRUGUPDATES, EMBASE, PHAR, PROMT, TOXCENTER,
 USAN, USPATFULL
 Other Sources: WHO




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

74 REFERENCES IN FILE CA (1962 TO DATE)
 48 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 74 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:174771

REFERENCE 2: 137:165559
 REFERENCE 3: 137:145521
 REFERENCE 4: 137:10850
 REFERENCE 5: 136:4197
 REFERENCE 6: 135:253844
 REFERENCE 7: 135:177389
 REFERENCE 8: 135:146180
 REFERENCE 9: 135:42801
 REFERENCE 10: 134:323118

L38 ANSWER 30 OF 30 REGISTRY COPYRIGHT 2002 ACS
 RN 66516-08-3 REGISTRY
 CN Glycine, N-(mercaptopropionyl)glycyl- (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Glycine, N-[N-(mercaptopropionyl)glycyl]-
 OTHER NAMES:
 CN Mercaptoacetyl diglycine
 FS 3D CONCORD
 MF C6 H10 N2 O4 S
 LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10 REFERENCES IN FILE CA (1962 TO DATE)
 5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 10 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 132:233676
 REFERENCE 2: 127:28218
 REFERENCE 3: 121:53220
 REFERENCE 4: 120:259847
 REFERENCE 5: 120:186299
 REFERENCE 6: 120:93865
 REFERENCE 7: 117:247830
 REFERENCE 8: 117:166771
 REFERENCE 9: 90:116647
 REFERENCE 10: 89:110353